STCube

STCube Acquisitions (Net)

The Acquisitions (Net) of STCube (052020.KQ) as of Oct 26, 2026 is -39.99 B KRW. In the previous year, Acquisitions (Net) was 14.76 B KRW — a change of -370.94% (lower).

Acquisitions (Net)

-39.99 BKRW

YoY

-370.94%

Last updated:

Acquisitions (Net) of STCube is 2024 -39.99 B KRW. Acquisitions (Net) of STCube was 2023 14.76 B KRW. It decreases by -370.94% lower compared to the previous year.

The STCube Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
-49.40 M KRW
Jan 1, 2018
-19.85 B KRW
Jan 1, 2019
-3.10 B KRW
Jan 1, 2020
10.02 B KRW
Jan 1, 2021
10.23 B KRW
Jan 1, 2022
-26.40 B KRW
Jan 1, 2023
14.76 B KRW
Jan 1, 2024
-39.99 B KRW
The STCube Acquisitions (Net) history
YEARAcquisitions (Net)YoY
-39.99 BKRW-370.94%
14.76 BKRW-155.89%
-26.40 BKRW-358.14%
10.23 BKRW+2.11%
10.02 BKRW-422.87%
-3.10 BKRW-84.37%
-19.85 BKRW+40,079.96%
-49.40 MKRW+3.78%
-47.60 MKRW-102.92%
1.63 BKRW-57.03%
3.79 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Acquisitions (Net) of STCube is -39.99 B KRW in 2024.

Acquisitions (Net) of STCube changed from 14.76 B KRW to -39.99 B KRW, representing a -370.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) STCube since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — STCube

All Key Metrics — STCube